(TCMR), have been directly shown to correlate to increased granzyme B (GzmB) expression [13] [14] [15] . In renal allografts, the level of GzmB + lymphocytes are significantly higher in stages IA and IB compared to control biopsies 13, 14 , and predict rapid progression to severe ACR (TMCR grade II or higher) 13 . Clinical studies focused on quantifying RNA transcripts showed that elevated GzmB levels in blood or urine are correlated to early ACR (grade IB or lower) and precede clinical diagnosis of ACR in renal and islet transplant patients [16] [17] [18] [19] . Importantly, the activity of GzmB is also regulated by tissues locally; increased expression of the endogenous GzmB inhibitor serpin protease inhibitor 9 (PI-9) 20 was reported to be a potential mechanism for stable renal function in patients with subclinical ACR 14 by inhibiting the ability of GzmB to trigger apoptosis in target cells. These clinical studies provide direct support for targeting GzmB as an early indicator of ACR and highlight the need to develop new methods to measure the activity of GzmB within the context of the local tissue microenvironment.
A promising approach to noninvasively measure in vivo protease activity is the design and administration of engineered agents to investigate diseased tissue. These include activity-based imaging probes that emit fluorescent signals upon cleavage 21 , or selectively bind to the active form of proteases 22 . Recently, this approach was employed for in vivo imaging of GzmB activity during experimental myocarditis and monitoring the treatment efficacy of cancer immunotherapy with positron emission tomography (PET) probes that irreversibly bind to GzmB 23, 24 . Activity-based approaches using fluorescent reporters are limited to superficial sites due to tissue scattering, but can be used in deeper tissues with invasive procedures, such as during tumour resection 25, 26 . Here we engineer GzmB nanosensors that accumulate in allograft tissue to sense antigraft T cell activity by producing a signal that is shed into urine for noninvasive detection (Fig. 1 ). Our technology builds on our work on synthetic biomarkers [27] [28] [29] [30] [31] , which leverage the catalytic activity of proteases to amplify detection signals, as well as the enrichment of detection signals into urine, to allow ultrasensitive detection of early-stage disease. In preclinical skin graft models of rejection, our GzmB activity nanosensors allow noninvasive discrimination of early ACR, and indicate graft failure in recipients under subtherapeutic immunosuppression.
results
Engineering activity nanosensors against granzyme B. Our activity nanosensors are formulated by conjugating GzmB peptide substrates to the surface of a nanoparticle scaffold ( Fig. 2a) . A nanoparticle carrier extends the circulation half-life of GzmB peptide substrates ( Supplementary Fig. 1) 32 , which would otherwise be rapidly filtered into urine, and increases peptide accumulation in tissues by passive diffusion from the circulating vasculature. Protease cleavage of the nanosensor by GzmB triggers a pharmacokinetic switch by releasing peptide fragments locally, which are then remotely cleared into urine for noninvasive detection. Here we used iron oxide nanoparticles (IONPs) as they are tolerated well and are FDA-approved for clinical use as anaemia therapies, contrast agents and in thermal ablation 33, 34 . To increase biocompatibility and circulation half-life, we decorated IONPs synthesized in house 35 with polyethylene glycol (PEG) to reduce nanoparticle uptake by the reticuloendothelial system (RES) 36 . With moderate PEGylation (20:1 PEG to IONP ratio), the average hydrodynamic diameter of our IONPs was ~47 nm while the circulation half-life was increased to ~3 h in vivo ( Supplementary Fig. 2) . These values are consistent with previously reported values for clinically approved IONPs 34 .
To identify peptide substrates that are sensitive to cleavage by recombinant GzmB, we pooled 13 candidate substrates from published literature [37] [38] [39] [40] (Supplementary Fig. 3 ). These substrates were 6-12 amino acids in length and characterized by a consensus cleavage motif with isoleucine at position P4 and aspartic acid at P1 in the immediate N-terminal direction of the cleavage site. From our library, the substrate sequence AIEFD|SG resulted in the highest initial cleavage velocity by recombinant GzmB (Supplementary Fig. 3 ).
To determine cleavage efficiency of peptide substrates conjugated to a nanoparticle, we conducted Michaelis-Menten kinetic analysis and calculated a k cat /K M value of 1.09 × 10 4 M −1 s −1 . This value was similar in magnitude to reported values of GzmB cleavage of free substrates (Fig. 2b) 37, 40 and showed that co-presentation of substrates and PEG molecules ( Supplementary Fig. 4 ) on the surface of IONPs did not sterically hinder GzmB cleavage. To assess substrate specificity for GzmB, we exposed our probes to coagulation and complement proteases, as they are ubiquitous and found at high concentrations in circulating blood. Using saline samples spiked with recombinant proteases (Fig. 2c ), plasma samples spiked with Ca 2+ to trigger coagulation ( Fig. 2d and Supplementary Fig. 5 ), or heat aggregated ɣ-globulin (HAGG) to trigger complement ( Fig. 2e ,f), we did not observe detectable increases in fluorescence that would indicate cross-cutting of our probes. By contrast, our probes were markedly activated in all samples that contained recombinant GzmB. To further test the biocompatibility of our nanosensors, we assessed the level of membrane attack complex (MAC) in serum samples to quantify potential complement activation from a foreign surface. We found significant increases in MAC levels in samples incubated with HAGG, but by contrast, no elevation in MAC formation in the presence of our probes (P < 0.001, n = 3, Fig. 2f ). Taken together, our activity nanosensors are sensitive to GzmB cleavage, are not cross-cut by coagulation and complement cascades, and do not promote complement activity.
GzmB activity nanosensors detect alloreactive T cell killing.
During target cell killing, an immune synapse is formed between cytotoxic T lymphocytes (CTLs) and target cells, and cytotoxic granules are directionally released into the synaptic cleft. This mechanism is thought to increase the local concentration of effector molecules to enhance target cell entry and killing, as well as to decrease off-target cytotoxicity by limiting exposure of bystander cells to effector molecules 41, 42 . As self-protective mechanisms, CTLs express cell-surface cathepsins and intracellular serpin PI-9 to proteolytically degrade granzymes or inhibit their cleavage activity 20, 43 . Although the release of effector molecules is directed to the immune synapse, extracellular GzmB can be readily detected using standardized assays such as ELISpot. Moreover, cell-free GzmB levels have been used to monitor cytotoxic activity in vivo, such as with cancer and rheumatoid arthritis 44, 45 . Because our nanosensors are formulated to probe extracellular protease activity, we sought to quantify GzmB expression during T cell killing in both intracellular and extracellular spaces, and assess the ability of our nanosensors to detect anti-graft cytotoxicity ex vivo.
To validate that the nanosensors are sensitive to physiologically relevant concentrations of GzmB, we used a T cell killing assay composed of transgenic OT1 T cells, which recognize the peptide epitope SIINFEKL from chicken ovalbumin (OVA), and target EG7-OVA or EL4 cells that express or lack the OVA antigen, respectively 46 . We first verified intracellular expression of GzmB in activated OT1 T cells co-cultured with EG7-OVA target cells compared to EL4 controls ( Supplementary Fig. 6a,b ). To confirm protease activity of GzmB, we used commercial fluorogenic probes that produce fluorescent signals after intracellular cleavage by GzmB in target cells. Although GzmB activity was not significantly elevated in EL4 target cells, significant GzmB activity was observed in EG7-OVA cells at T cell to target cell ratios of 1:1 and 10:1 (P < 0.001, n = 3, Fig. 3a -c). To quantify the amount of GzmB secreted into the extracellular space, we analysed co-culture supernatants by ELISA and detected an approximately 10-fold increase in GzmB between EG7-OVA and EL4 samples at a 10:1 ratio (P < 0.0001, n = 3, Fig. 3d ), which indicated that significant amounts of GzmB were released into the extracellular space. Under these co-culture parameters, we incubated fluorescently labelled nanosensors with conditioned supernatant and detected significant increases in initial cleavage velocities (V o ) at an OT1: EG7-OVA ratio of 10, which was consistent with the level of extracellular GzmB as quantified by ELISA ( Fig. 3e,f) . In co-cultures containing equal numbers of OT1 T cells and EG7-OVA target cells, nanosensors were activated by secreted GzmB concentrations of ~1.7 pM (~50 pg ml −1 ) ( Fig. 3d,f) , which was several orders of magnitude lower than reported concentrations (100-500 nM) that have been used to induce in vitro target cell death [47] [48] [49] . These data confirmed that protease activity amplifies detection signals to allow our GzmB nanosensors to sense cytotoxic T cell activity. We next sought to further test the sensitivity of nanosensors against alloreactive T cells. We collected splenocytes and lymphocytes from recipient C57BL/6 mice that were either transplanted with skin allografts from major histocompatibility complex (MHC) mismatched BALB/c donor mice or isografts from donor C57BL/6 mice. Co-incubation of harvested allograft cells with BALB/c splenocytes and nanosensors resulted in significant increases in GzmB activity as monitored by sample fluorescence, which was not detected in samples co-cultured with T cells harvested from isograft mice ( Fig. 3g,h) . These results show that GzmB activity nanosensors detect alloreactive T cell killing activity.
Urinary pharmacokinetic switch enables remote detection. We next set out to establish the potential of using GzmB activity nanosensors to probe anti-graft T cell activity in vivo. During posttransplant tissue injury, damage-associated molecular patterns (DAMPs) trigger the release of proinflammatory cytokines (for example, TNF-ɑ and IL-6) by innate immune cells that increase local vessel permeability, blood flow and immune cell infiltration 4, 50, 51 . By histopathology, classifications of early-stage T cell rejection (borderline TCMR, TCMR IA and TCMR IB) all indicate interstitial inflammation as a defining feature 52 . Localized vasodilation enhances delivery and accumulation of nanomedicines to inflamed disease sites, as demonstrated by previous studies targeting atherosclerotic plaques and tumours [53] [54] [55] . To produce a diagnostic signal in urine, activity nanosensors are formulated with a nanoparticle core that functions to passively target allograft tissue and initiate a pharmacokinetic switch whereby surface substrates are cleaved by local GzmB activity and then traffic into urine for analysis. Thus, we sought to quantify the extent to which the components of our nanosensors (that is, peptide and IONP) accumulate in inflamed allograft tissue as well as the size-dependent trafficking of GzmB reporter signals to urine during rejection.
To assess IONP organ distribution, we intravenously administered surface-labelled IONPs to recipient C57BL/6 mice simultaneously transplanted with both skin allografts and isografts to directly compare targeting by full-body fluorescent imaging ( Fig. 4a ). We found significant accumulation of nanosensors in allografts as early as postoperative day (POD) 3 compared to isograft controls. Preferential accumulation peaked on POD 7 with 4-fold signal increase over skin isograft (P < 0.01, n = 5) and was statistically equivalent by POD 9, which we attributed to tissue necrosis, scab formation and vascular occlusion characteristic of late-stage rejection of allografts ( Fig. 4a,b and Supplementary Fig. 7 ). To assess biodistribution, we found higher levels of IONPs in organs with fenestrated endothelium (liver, spleen and lymph nodes) over others (brain, heart, kidney and lung)-which was consistent with the vast majority of nanomedicines 53,55 -and no significant differences across all organs between allograft and isograft cohorts of mice ( Supplementary Fig. 8 ). These studies were performed postmortem and did not allow direct quantification of IONPs in the bladder due to spontaneous voiding of urine resulting from the relaxation of urethral sphincter muscles. Therefore, we used live whole-animal fluorescent imaging and found no accumulation of IONPs in the bladders of mice, which is consistent with the kidney size filtration limit (~5 nm) previously shown for inorganic nanomaterials 56 ( Supplementary Fig. 9a -c). To examine peptide pharmacokinetics, we administered free fluorophore-labelled GzmB substrates and found significant increases in perfusion in allograft tissue compared to isograft controls (P < 0.05, n = 3, Supplementary  Fig. 9d-f ), but statistically equivalent clearance into urine between allograft-and isograft-bearing animals ( Supplementary Fig. 9g ,h). These data showed that free IONPs and GzmB substrates accumulate in allograft tissue. Next, to investigate the sites of GzmB activation in vivo, we designed an activatable probe where the fluorophore is proximal to the IONP surface and remains attached after cleavage while the quencher is released (Fig. 4c ). This design prevents fluorescent signals from being washed away and allows tissue localization of fluorescent IONPs. We first verified probe activation in vitro by recombinant GzmB (Supplementary Fig. 10a -c), and in vivo, found that probe activation was significantly increased in allograft skin but statistically equivalent in all major organs (P < 0.0001, n = 5, Fig. 4d and Supplementary Fig. 11 ). To visualize peptide cleavage and trafficking of fluorescent reporter fragments into urine, we infused IONPs conjugated with homoquenched GzmB substrates ( Supplementary Fig. 12 ) and analysed major organs by fluorescent imaging (Fig. 4e ). In allograft mice, we found 3-fold higher fluorescence in kidneys compared to isograft mice (P < 0.0001, n = 4-5, Fig. 4f and Supplementary Fig. 13 ), which we attributed to active renal filtration of cleaved peptide fragments. This observation was further supported in live animal imaging, where we observed increases in fluorescent signals in bladders of allograft mice ( Fig. 4g ). Collectively, our data showed that GzmB activity nanosensors preferentially accumulate and activate in allograft tissue during rejection, and after cleavage, peptide fragments are efficiently cleared into host urine.
Noninvasive and early detection of ACR.
Histological criteria for staging severity of ACR include features such as tissue damage and the presence of apoptotic cells 57 , which are downstream effects of anti-graft T cell responses. Activity measurements of proteases that drive disease pathology have the potential to be early biomarkers and anticipate disease trajectory, such as using matrix metalloproteinase (MMP) activity to predict liver fibrosis progression and regression 27, 28 . We therefore investigated the potential of using GzmB activity nanosensors for the early detection of ACR ( Fig.  5a ). To quantify skin graft health and rejection kinetics, we assigned a score of 4 for healthy allografts, a score of 0 for full rejection, and intermediate scores based on features such as the ratio of viable to necrotic skin and the presence of ulcerations or scabs. According to these metrics, graft scores began to significantly decrease at day 9 after transplant (2.5 vs 3.9, P < 0.0001; Fig. 5b ,c and Supplementary  Fig. 14) and reached the endpoint when allografts were completely rejected within two weeks post-transplantation. To identify the earliest timepoint of GzmB upregulation, we analysed activated CD8 + T cells from spleens and draining lymph nodes at days 5, 7 and 9. While GzmB levels at day 5 were unchanged compared to controls, we detected an increase in the frequency of GzmB-expressing CD8 + T cells in allograft animals by day 7 ( Supplementary Fig. 15 ) when graft scores remained statistically equivalent between allograft and isograft tissues. To support our findings, we analysed graft tissue on day 7 by immunohistochemistry and found significant increases in both graft-infiltrating CD8 + T cells and GzmB expression ( Fig. 5d-g) . Taken together, our data provided evidence that GzmB levels were significantly upregulated in allograft tissue at the onset of acute rejection.
To determine conditions for serial monitoring, we first evaluated the immunogenicity of our formulation and found that GzmB peptides or nanosensors do not induce neutralizing antibodies when coinjected with or without complete Freud's adjuvant ( Supplementary  Fig. 16 ). Moreover, we analysed residual urinary fluorescence from a single injection and found full clearance within 2 days after administration ( Supplementary Fig. 17 ). Based on these results, we sought to determine how early our system can detect the onset of ACR by administering nanosensors and performing urinalysis in transplanted mice before transplantation (POD −4) and on early PODs at 2-day intervals (PODs 3, 5 and 7). Using pre-graft urine signals as a baseline for recipients, we did not detect significant elevations in post-graft urine signals from naive, isograft and CD8 + -depleted control cohorts of mice ( Fig. 5h and Supplementary Fig. 18a,b ). By contrast, post-graft urine signals from allograft recipients were sig- , isograft mice (n = 8) and CD8depleted allograft mice (paired two-sided Student's t-test, n = 6, P = 0.08; ns, not significant). Right: normalized urine fluorescence after administration of nanosensors to allograft mice before and at selected days after transplant surgery (one-way ANOVA with Dunnett post-test and correction for multiple comparisons, **P < 0.01, ****P < 0.0001, n = 6). Urine signals were quantified as percent injected dose before normalized by pre-transplant signals. i, Receiver-operating-characteristic (ROC) analysis showing the diagnostic specificity and sensitivity of activity nanosensors in differentiating between allografts (n = 6) from isografts (n = 8) on POD 7 (AUC = 0.982, 95% CI = 0.937-1.027) and POD 5 (AUC = 0.667, 95% CI = 0.354-0.979).
nificantly elevated as early as POD 5 (P < 0.01, n = 6) and further increased by POD 7 (P < 0.0001, n = 6, Fig. 5h ), detecting GzmB activity several days before graft scores were statistically significant between allografts and isografts (Fig. 5c ). To assess sensitivity and specificity, we analysed urine signals by receiver-operating-characteristic (ROC) analysis and quantified an increase in AUROC from 0.67 to 0.98 by POD 7 (95% confidence interval of 0.94 to 1.03). Altogether, these results illustrate that systemic administration of GzmB activity nanosensors in allograft recipients produce urine signals that classify ACR with high sensitivity and specificity.
The use of immunosuppressive drugs as maintenance therapy has significantly reduced the rates of ACR; however, rejection episodes may occur despite ongoing immunosuppression, or in patients treated with subtherapeutic doses 58, 59 . To assess the sensitivity of this approach to detect T cell activity under immunosuppression, we performed urinalysis of allograft-bearing mice treated with the calcineurin inhibitor (CNI) tacrolimus, which directly inhibits downstream calcium-dependent signalling events in T cells (Fig. 6a ). Daily treatment with high-dose tacrolimus (2 mg kg −1 ) improved skin allograft outcome as quantified by both graft scores and survival curves, but was subtherapeutic and did not prevent eventual graft loss due to MHC-mismatched donor and recipient mice (Fig. 6b,c) . Compared to pre-graft urine signals on POD −4 ( Fig. 6d and Supplementary Fig. 19 ), post-graft urine signals were significantly elevated on POD 7 (P < 0.05, n = 6) and POD 12 (P < 0.01, n = 6), which indicated elevated GzmB activity in recipient mice under subtherapeutic immunosuppression. However, as anticipated by direct inhibition of T cell activity with CNIs, urine signals from treated mice were blunted compared to untreated mice (Fig. 6e) . These results showed that our urine measurements are sensitive to GzmB activity under subtherapeutic immunosuppression and provide an early indicator of eventual graft failure.
Discussion
Invasive core biopsy is considered the gold standard for diagnosing ACR; however, it is associated with significant patient morbidity and sampling variability, and provides only a static snapshot of anti-graft activity 7, 8 . Here, we developed GzmB activity nanosensors, consisting of an IONP core decorated with peptide substrates, to sense CD8 + T cell killing. In a skin graft mouse model of ACR, these nanosensors accumulate in allograft tissue and are cleaved locally by GzmB, which then triggers a pharmacokinetic switch to enable detection of peptide fragments in the urine. Our nanosensors noninvasively detect the onset of ACR with high sensitivity and specificity, and in allograft mice under subtherapeutic immunosuppression, produce urine signals that precede eventual graft failure.
The use of a nanoparticle carrier increases circulation half-life of substrate peptides, which are otherwise cleared from the body by renal filtration within minutes after intravenous administration 32 . Without conjugating peptides to a nanoscale scaffold larger than the glomerulus pore size of ~5 nm 60 , urine samples would otherwise be confounded with uncleaved peptide substrates. We selected IONPs because they are FDA-approved and well-tolerated in humans 33 , but alternative formulations with different carriers (for example, PEG or dextran) can be used to tune pharmacokinetics 30 . Here we leveraged graft inflammation during early ACR 52,61,62 to passively deliver nanosensors. Because skin transplants are initially avascular, we anticipate that passive targeting may be enhanced for vascularized solid transplants (for example, kidney, liver or heart), particularly for organs with porous, fenestrated endothelium such as the liver. Given the wealth of targeting and delivery strategies in nanomedicine, this system will be amenable to functionalization with organspecific or inflammation-targeting ligands 63, 64 to direct delivery to specific anatomical sites or enhance diagnostic signals 65 .
Our study focused on GzmB activity as an early biomarker for ACR. Clinical studies have shown that increased expression of GzmB is found in allograft tissue during Banff TCRM IA and IB, precedes progression to grade II or higher, and has the potential to predict graft outcomes 13, 14, 17, 19, 66 . To measure protease activity in vivo, existing activity-based sensors are designed to produce a localized fluorescent signal, which is subject to tissue scattering and washout by blood, which attenuates the strength of the detection signal 21, [67] [68] [69] [70] . By contrast, our technology is based on local cleavage and remote detection of cleaved reporters enriched in urine, which amplifies detection signals to increase the sensitivity for early-stage analysis. Noninvasive biomarkers that rely on shed molecules or the contents of dead cells 10,11 experience significant dilution in blood and may be limited for early-stage detection 71, 72 . While the performance of this method for ACR detection in a preclinical setting (AUROC = 0.98) compares favourably to other biomarkers, such as serum creatinine (0.63), NGAL (0.6-0.9), KIM-1 (0.8) and cystatin C (0.64-0.82) [73] [74] [75] [76] , the translation of this approach will require rigorous evaluation in humans and guidance by regulatory and community qualifications 77 .
The use of CNIs such as tacrolimus is closely monitored in patients to maintain graft tolerance and target blood concentrations 78 . In our study, the tacrolimus dose was subtherapeutic despite administration at doses (2 mg kg −1 ) 20-200-fold higher compared to those given to human patients, and did not prevent eventual graft loss in mice. This discrepancy in dose results from the use of MHC-mismatched donors and recipients in skin graft models to allow ACR to occur within a reasonable experimental window (~7-10 days). In humans, donor and recipient MHC matching allows the use of lower effective concentrations of CNIs to induce and maintain graft tolerance. Our study showed that urine measurements of GzmB activity anticipated eventual graft failure in mice under subtherapeutic immunosuppression, which may allow for dose adjustment or additional therapeutic interventions in patients.
In the future, this technology will benefit by expanding our single GzmB probe into a family of nanosensors designed to sense different proteases, which can be accomplished by the use of mass barcodes that uniquely label each peptide substrate for multiplexed quantification by mass spectrometry 27 . We anticipate that a family of activity sensors against a panel of proteases (for example, T cell, fibrosis and viral proteases) will allow staging of ACR and discrimination between different injuries that likewise depend on CD8 + T cell cytotoxicity. These include the ability to differentially diagnose anti-graft from anti-viral activity (for example, BK, CMV or HCV) that occurs with high prevalence in transplant patients 79 . The expanded library may also include proteases from the complement cascade to allow monitoring of antibody-mediated rejection (AMR), which is responsible for the majority of long-term graft loss 80 , or organ-specific proteases (for example liver protease hepsin) for signal normalization. These improvements may provide the capacity to differentiate ACR from AMR with high diagnostic power, and resolve anti-graft activity into the relative contributions of each mechanism to personalize management of transplant recipients.
Methods
Animals. Six-to eight-week-old male mice were used at the outset of all experiments. OT1 transgenic mice (C57BL/6-Tg(TcraTcrb)1100Mjb/J) were purchased from Jackson Laboratories. C57BL/6 and BALB/c mice for skin graft experiments and CFW control mice were purchased from Charles River Laboratories. All animal protocols were approved by Georgia Tech IACUC (protocol no. A14100) and Emory University IACUC (protocol no. DAR-2002797-082117GN). All authors have complied with relevant ethical regulations while conducting this study.
Nanosensor synthesis and characterization. Aminated IONPs were synthesized in-house according to the published protocol 35 . FITC-labelled GzmB substrate peptides ((FITC)AIEFDSGc; lower case letters = d-form amino acids) were synthesized by Tufts University Core Facility and used for in vivo formulation. FITC-labelled GzmB substrate peptides with internal quencher ((5-FAM) aIEFDSGK(CPQ2)kkc) were synthesized by CPC Scientific and used for all in vitro activity assays. Aminated IONPs were first reacted to the heterobifunctional crosslinker succinimidyl iodoacetate (SIA; Thermo) for 2 h at room temperature (RT), and excess SIA was removed by buffer exchange using the Amicon spin filter (30 kDa, Millipore). Sulfhydryl-terminated peptides and polyethylene glycol (PEG; LaysanBio, M-SH-20K) were mixed with NP-SIA (90:20:1 molar ratio) and reacted overnight at RT in the dark to obtain fully conjugated activity nanosensors. Activity nanosensors were purified on a Superdex 200 Increase 10-300 GL column using the AKTA Pure FPLC System (GE Health Care). Ratios of FITC per IONP were determined using absorbance of FITC (488 nm, ε = 78,000 cm −1 M −1 ) and IONP (400 nm, ε = 2.07 × 10 6 cm −1 M −1 ) 35, 81 measured with a Cytation 5 plate reader (Biotek). At this conjugation condition, our resulting formulations have an average of 50 FITC-labelled peptides per nanoparticle core. DLS measurements of activity nanosensors were done in PBS or mouse plasma at RT using Zetasizer Nano ZS (Malvern).
In vitro protease cleavage assays. Activity nanosensors (6 nM by NP, 300 nM by peptide) were incubated in PBS + 1% bovine serum albumin (BSA; Sigma) at 37 °C with murine granzyme B (0.17 µM; Peprotech), human thrombin (13.5 µM; HaemTech), mouse thrombin (12.5 µM; HaemTech), mouse plasmin (2.94 µM; HaemTech), C1r (1.43 µM; Sigma), C1s (1.80 µM; Sigma), factor D (0.20 µM; Sigma), factor I (0.79 µM; Sigma) and MASP2 (0.08 µM; Biomatik). Sample fluorescence was measured for 60 min using a Cytation 5 plate reader (Biotek). To optimize GzmB substrate, a library of potential substrates was synthesized by the Tufts University Core Facility peptide synthesis service and conjugated to IONPs. Cleavage assays of nanoparticles decorated with these substrates with recombinant GzmB were performed, and data was fitted to compare initial cleavage velocities. To determine Michaelis-Menten constants, cleavage assays with GzmB were performed at different substrate concentrations. To initiate the coagulation cascade, citrated plasma was mixed with activity nanosensors before addition of calcium chloride (15 mM, Sigma). To initiate complement activation, control human serum (Sigma) was mixed with activity nanosensors before addition of heat aggregated ɣ-globulin (HAGG; Quidel) according to the manufacturer's protocol. After measuring fluorescence for 1 h, supernatants were collected and measured for formation of MAC complex using a MicroVue CH50 Eq EIA Kit (Quidel).
GzmB characterization in transgenic T cell co-cultures.
EL4 and EG7-OVA cells (ATCC) were grown in RPMI 1640 supplemented with 10% FBS and 25 mM HEPES (Gibco). EG7-OVA cultures were supplemented with G418 (0.4 mg ml −1 , InvitroGen). CD8 + T cells were isolated from OT1 splenocytes (Jackson Labs) by MACS using CD8a microbeads (Miltenyi). Cells were activated by seeding in 96well plates pre-coated with anti-mouse CD3e (1 µg ml −1 working concentration; clone: 145-2C11, BD) and anti-mouse CD28 (2 µg ml −1 working concentration; clone: 37.51, BD) at 2 × 10 6 cells ml −1 in RPMI 1640 supplemented with 10% FBS, 100 U ml −1 penicillin-streptomycin, 1X non-essential amino acids (Gibco), 1 mM sodium pyruvate, 0.05 mM 2-mercaptoethanol and 30 U ml −1 hIL-2 (Roche). After 2 days, cells were washed and transferred to uncoated plates. On day 5, 1 × 10 6 activated OT1 T cells were coincubated with 1 × 10 6 EL4 or EG7-OVA cells for 2 h at 37 °C and stained for GzmB using anti-mouse GzmB (clone: NGZB, eBioScience) and the Intracellular Fixation & Permeabilization Buffer Set (eBioScience, 88-8824-00). To measure GzmB activity inside target cells, we coincubated activated OT1 CD8 + T cells with EL4 and EG7-OVA target cells at various T cell to target cell ratios and stained them using a GranToxiLux Kit (OncoImmunin, GTL702-8). To measure secretory GzmB, we collected the coculture supernatant of OT1 with target cells and performed an ELISA with a Granzyme B Mouse ELISA Kit (eBioScience, BMS6029).
Nanosensor assay sensing T cell killing.
To sense transgenic T cell killing, CD8 + OT1 T cells were isolated and activated according to the protocol outlined above. On day 5 after activation, 1 × 10 5 OT1 T cells were coincubated with 1 × 10 5 EL4 or EG7-OVA target cells for 2 h at 37 °C. Co-culture supernatants were mixed with activity nanosensors (2 nM by NP and 100 nM by peptides) and fluorescence was monitored for 1 h at 37 °C. To sense alloreactive T cell killing, on POD 7, CD8 + T cells were isolated from splenocytes and lymphocytes of skin graft mice. 5 × 10 5 CD8 + T cells from skin graft mice were restimulated with 5 × 10 5 splenocytes from BALB/c mice (Charles River) for 6 h at 37 °C. Coculture supernatants were mixed with activity nanosensors (2 nM by NP and 100 nM by peptides) and fluorescence was monitored for 2 h at 37 °C. Skin graft surgery. Recipient C57BL/6 animals (Charles River) were administered intraperitoneally an anaesthetic cocktail of ketamine (100 mg kg −1 ; GT PRL) and xylazine (100 mg kg −1 ; GT PRL) followed by sustained-released buprenorphine (1 mg kg −1 , intraperitoneal; GT PRL) right before surgery. The hair was shaved from the upper lateral thoracic walls of the recipient animal before surgery. The surgical site was cleaned 3 times, alternating between isopropyl alcohol (GT PRL) and chlorhexidine (GT PRL). Donor BALB/c or C57BL/6 animals (Charles River) were euthanized under isoflurane sedation by cervical dislocation. Segments of tail skin (each approximately ~1 cm 2 ) was removed from the donor animals and kept in sterile saline on ice until the grafting procedure. In recipient C57BL/6 mice, the skin on the lateral thoracic walls was removed using surgical scissors to create a defect of similar size to the segment of tail skin. The donor skin was then placed over the site to cover the wound defect. The site was protected by wrapping a commercial bandage that covered the graft site and firmly wrapped around the body of the animal.
Skin graft scoring and survival analysis. Skin grafts were qualitatively scored on a scale ranging from 0-4 according to established protocol by the Emory Transplant Center. Scoring involved direct observation and palpation of the graft and surrounding tissue. A score of 4 is for a perfect-appearing skin graft. If donor was of BALB/c origin, the grafted skin with a score of 4 would be light pink and slightly velvety, with hair growing from the graft and no imperfection noted. A score of 3 is for grafts that are good but not perfect in appearance, such as a graft that might otherwise merit a 4 but for a single red ulcer comprising less than 25% of the graft area. Other reasons for a score of 3 might be faint scabbiness over the ear skin graft or slight hardening at the edges of a tail skin graft. A score of 2 is given for grafts that are half necrotic. For example, half of the graft area may be covered by red ulcers or scaly, red, thickened skin, but half of the graft still consists of viable skin. Grafts that have shrunk to 50% of their original size receive a score of 2. A score of 1 is given for grafts that are nearly completely necrotic but still have some small areas of viable skin. Grafts with a score of 1 will typically be totally necrotic within one week. A score of 0 is given when a graft has been fully rejected and the transplanted skin is completely necrotic. For Kaplan-Meier survival analysis, a skin graft was considered rejected when its score was below 1.
Measurement of circulation half-life.
For all half-life characterization, VT750labelled nanosensors (20 µg by mass, 10 nmol by peptide) or peptides (10 nmol) were administered intravenously to control CFW mice (Charles River). At several time points following administration, blood was collected into heparin-coated capillary tubes (VWR) via retro-orbital collection and imaged using Odyssey CLx Imaging System (LI-COR). A ladder with known concentrations of NIR dye was imaged at the same time to correlate sample fluorescence to dye concentrations.
Pharmacokinetic studies. Mice bearing skin grafts were administered with nanosensors (20 µg) or peptides (10 nmol) labelled with VivoTag S-750 (VT750; PerkinElmer). Nanosensors and peptides were labelled with VT750 (3:1 molar ratio) using NHS chemistry per manufacturer's protocol. For organ biodistribution, whole mice were imaged with IVIS Spectrum CT Imaging System (PerkinElmer) while excised organs were imaged with Odyssey CLx Imaging System (LI-COR) 24 h after administration. For urine pharmacokinetics, whole mice were imaged with IVIS Spectrum CT Imaging System (PerkinElmer) at 90 min post administration. To track cleaved fragments after in vivo GzmB cleavage, on day 7 post-transplant, VT750-labelled activity nanosensors (10 nmol by peptides) were administered to skin graft mice. At 90 minutes post administration, the whole mouse was imaged with IVIS Spectrum CT Imaging System (PerkinElmer) to analyse the extend of fluorescence from the bladder. Major organs were then excised and homogenized using Lysing Matrix A Tubes and FastPrep24 Homogenizer (MP Biomedicals). Tissue homogenates were transferred to a 96-well plate and then imaged with the Odyssey CLx Imaging System (LI-COR).
GzmB activity imaging. GzmB substrate peptides with non-natural amino acids for manual labelling (kGGsIEFDSGGGs{PRA}c) was purchased from Genscript. After the peptides were coupled to IONPs, the NIR dye IRDye-800CW (LICOR) was couple to L-propargylglycine (PRA) via copper catalysed click chemistry 82 . The NIR quencher was then coupled to the N-terminal lysine via traditional NHS chemistry according to the manufacturer's protocol to generate the NIR GzmB activity probes. The extent of successful quenching and enzymatic activation were analysed in vitro by absorbance analysis and LICOR imaging upon addition of recombinant GzmB (Peprotech). For in vivo GzmB activity imaging study, NIR GzmB activity probes (10 nmol by peptide) were administered to skin graft mice. Major organs were excised at 24 h and imaged with the Odyssey CLx Imaging System (LICOR).
GzmB characterization in skin graft mouse model. For histological analysis, tissues were collected from skin graft mice on POD 7. All tissues were fixed in 4% paraformaldehyde (EMS) overnight at 4 °C, washed 3 times with PBS and stored in 70% ethanol (VWR) until paraffin embedding, sectioning and staining for GzmB and CD8 (Winship Pathology Core). For flow cytometry analysis, 1 × 10 6 splenocytes or lymphocytes isolated from skin graft mice on PODs 5, 7 and 9 were restimulated with 1 × 10 6 BALB/c splenocytes for 6 h at 37 °C before staining for GzmB using anti-mouse GzmB (clone: NGZB, eBioScience) and an Intracellular Fixation & Permeabilization Buffer Set (eBioScience).
Urinary prediction of acute rejection in skin graft mice. All urinalysis experiments were done in paired setup. Before (POD −4) and at various time points after transplantation, skin graft mice were administered with FITC-labelled activity nanosensors (10 nmol by peptides). Mice were placed over 96-well polystyrene plates surrounded by an open cylindrical sleeve covered by a weighted petri dish to prevent animals from jumping out of the cylinder. Animals were left to urinate for 90 min before urine samples were collected. FITC in urine was purified by a magnetic separation assay using Dynabeads (Thermo, 65501) coated with anti-FITC antibody (GeneTex, GTX10257) according to manufacturer's protocol. Fluorescent signals were measured with Cytation 5 Plate Reader (Biotek). Concentrations of FITC from urine samples were calculated using a free FITC ladder and normalized with urine volume to obtain percent injected dose. To account for batch-to-batch differences in nanosensors, the percent of injected dose is normalized by the average and variance to pre-transplant signals and plotted as normalized urine fluorescence.
In vivo CD8 + T cell depletion. For CD8 + depletion study, mice were given antimouse CD8 (clone: 53-6.7, BioXCell) for 3 consecutive days following with booster shots every 3 days after. Flow cytometry analysis of splenocytes and lymphocytes were performed with anti-mouse CD3 (clone: 17A2, Biolegend), anti-mouse CD4 (clone: RM4-5, Biolegend), anti-mouse CD8 (clone: KT15, Serotec) to confirm success of depletion.
Administration of immunosuppression.
For drug response study, allograft mice were given either tacrolimus (2 mg kg −1 , intraperitoneal; Prograft) or saline every day starting from POD −1 until POD 7. Mice were given two more injections on PODs 9 and 11.
Immunogenicity study. On POD 0, C57BL/6 mice were inoculated intraperitoneally with 200 µl of GzmB peptide (10 nmol), GzmB nanosensors (10 nmol by peptide), GzmB nanosensors (10 nmol by peptide, 100 µl) + complete Freund's adjuvant (CFA, 100 µl; Sigma), chicken ovalbumin (100 µg, 100 µl; Sigma) + CFA (100 µg) and saline. Blood was collected via retroorbital blood draw into serum collection tube (CAPIJECT) and centrifugated for 5 min at 3,500g. Serum samples were collected and stored at −80 °C until analysis. Total IgG levels in serum was determined using an Easy-Titer Mouse IgG Assay Kit (Thermo).
Software and statistical analysis. Graphs were plotted and appropriate statistical analyses were conducted using GraphPad Prism (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; central values depict the means, and error bars depict s.e.m.).
Quantification of histological images was performed on ImageJ (NIH). Wholemouse fluorescent data were analysed using Living Image (PerkinElmer). Whole-organ fluorescent data were analysed using Image Studio (LI-COR). Flow cytometry data were analysed using FlowJo X (FlowJo, LLC). Power analyses were performed using G*Power 3.1 (HHUD).
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability
All data supporting the findings of this study are available within the manuscript and its Supplementary Information. Raw data are available from the corresponding authors. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
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For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection
Fluorescent data from microplate were collected with Gen5 2.07 (Biotek). Whole-mouse fluorescent data were collected with Living Image 4.4.5 (PerkinElmer). Whole-organ fluorescent data were collected with Image Studio 5.2 (LI-COR). Flow-cytometry data were collected with BD FACSDIVA v8 (BD Biosciences).
Data analysis
Quantification of histological images was performed on ImageJ mod Fiji 1.51n. Whole-mouse fluorescent data were analysed using Living Image 4.4.5 (PerkinElmer). Whole-organ fluorescent data were analysed using Image Studio 5.2 (LI-COR). Flow-cytometry data were analysed using FlowJo X (FlowJo, LLC). Graphs were plotted and appropriate statistical analyses were conducted using GraphPad Prism 6.05 (*P< 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; all error bars depict s.e.m.).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub 
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
Power analyses were performed (G*Power 3.1.9.2) to determine sample size, taking into account the effect size (dz) from preliminary data. For in vivo urinalysis experiments, using a conservative approach (dz between 1 and 2.2), we estimated that our experiments required a minimum of 4-9 animals to reach statistical power equal to or greater than 0.8.
Data exclusions No data were excluded from the analyses.
Replication
All attempts at replication were successful. Furthermore, to ensure reproducibility of the experimental findings, in addition to replicating the experiments with biological replicates, we often used several experimental methods to confirm a particular finding. For example, GzmB expression in the skin-graft model was confirmed by both flow cytometry and immunohistochemistry. Similarly, the ability of nanosensors to detect the early onset of rejection was confirmed qualitatively with NIR fluorescent imaging and quantitatively with an urine assay.
Randomization Animals with the same age and sex were allocated into experimental groups randomly.
Blinding
The majority of experiments (nanosensors cleavage assay, T-cell assays, NIR fluorescence imaging, and urine assays) were done with knowledge of group allocations during data collection. This was because skin allografts are from C57BL/6 (black skin) whereas isografts are from BALB/c (white skin). Regardless, each mouse has an ear tag to facilitate downstream identification. All downstream analyses were done without knowledge of group allocation.
Reporting for specific materials, systems and methods Obtaining unique materials FITC-labeled custom peptides were synthesized by Tufts University Peptide Core. Custom peptides with fluorophore-quencher pair for in vitro cleavage assays were synthesized by CPC Scientific. All custom materials can be purchased directly from these commercial sources.
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Antibodies Antibodies used For plate activation of splenic CD8+ T cells: anti-mouse CD3e (Clone: 145-2C11, BD), anti-mouse CD28 (Clone: 37.51, BD). For flow cytometry analysis: anti-mouse GzmB (Clone: NGZB, eBioScience), anti-mouse CD3 (clone: 17A2, Biolegend), anti-mouse CD4 (clone: RM4-5, Biolegend), anti-mouse CD8 (clone: KT15, Serotec). All antibodies for flow analysis were used at 100x dilution. For histological analysis: anti-mouse or human GzmB (1/100 dilution, polyclonal, product #ab4059, Abcam), anti-mouse CD8a (1/500 dilution, polyclonal, product #ab203035, Abcam)
Validation
Antibody staining was compared to manufacturer's QC data. Furthermore, antibodies were validated by inclusion of positive and negative controls in experiments, as well as by using orthogonal methods such as ELISA. 
Eukaryotic cell lines

Mycoplasma contamination
All cell lines were tested negative for mycoplasma contamination.
Commonly misidentified lines (See ICLAC register)
No commonly misidentified cell lines were used in this study.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals
OT-1 mice are transgenic mice in which their T cells have been genetically engineered to recognize only one specific antigen, instead of a broad range of antigens that T cells in a wild-type mouse would normally recognize. The antigens are chicken ovalbumin (OT-1). T cells from OT1 mice are used as the model of antigen specific T cell killing. We used C57BL/6 mice as recipients for grafts from BALB/c mice because their MHC molecules are mismatched, and therefore, promotes T cell mediated acute rejection.
All mice used in this study were female and 6-8 weeks old.
Wild animals
The study did not involve wild animals.
Field-collected samples
The study did not involve samples collected from the field.
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology Sample preparation
For flow-cytometry experiments, single cells were isolated from spleens and lymph nodes of mice using standard protocols. Tissues were dissociated between frosted glass slides (VWR 48312-004) and filtered with a 40-μm cell strainer (VWR 10199-654). RBC were lysed with RBC lysis buffer (VWR 420301-BL). Cell count and viability of the final single-cell suspension were determined by Trypan Blue staining with Countess II FL Cell Counter (Thermo).
Instrument
Data for the flow-cytometry experiments were collected using BD LSR Fortessa (BD Biosciences).
Software
Flow-cytometry data were collected with BD FACSDiva v8 (BD Biosciences). Analyses were done in FlowJo X (FlowJo, LLC).
Cell population abundance No sorting experiments were done in these studies. For flow-cytometry experiments, each sample contained 10^6 viable cells.
After staining, 3x10^5 total events were recorded for each sample before statistical tests were performed.
Gating strategy
A conservative gate was drawn on the FSC-A x SSC-A plot. Single cells were then gated using FSC-W x FSC-H plot. Live cells were
